HFA-ICOS Baseline Cardio-Oncology Risk Assessment for Combination Rapidly Accelerated Fibrosarcoma (RAF) and Mitogen-Activated Extracellular Signal-Regulated Kinase (MEK) Inhibitors
Stratifies cardiotoxicity risk in cancer patients scheduled to receive combination RAF and MEK inhibitors.
This tool is specifically for evaluating cardiotoxicity risk of RAF and MEK inhibitor therapies.
Other HFA-ICOS cardiotoxicity risk assessments are available for the following therapies:
Advice
This tool is a decision-support aid and should be used alongside clinician judgment, patient preferences, specialist expertise, and current evidence-based guidelines/local protocols; results should not be the sole determinant of care.
Management
- Low risk: Continue treatment with appropriate cardiovascular surveillance.
- Medium risk:
- Provide closer monitoring of cardiovascular health.
- Manage cardiovascular risk factors.
- Consider cardio-oncology or cardiology referral.
- High and very high risk:
- Discuss risks and benefits of proposed chemotherapy.
- Initiate closer cardiac monitoring.
- Refer for cardio-oncology or cardiology assessment to optimise risk factors and provide a personalised management plan.
- For more detailed guidance, please refer to the 2022 ESC guidelines.
Critical Actions
A referral to cardiology should be obtained for any patient who develops cardiotoxicity during therapy, regardless of initial risk.